Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En
about
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisNew targets in psoriatic arthritisTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter studyTreatment of nail psoriasis: common concepts and new trendsCumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study.Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA).Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version.Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.Burden of disease: psoriasis and psoriatic arthritis.Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.Patient involvement in outcome measures for psoriatic arthritis.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.Treat-to-target in spondyloarthritis: implications for clinical trial designs.Advances in the management of psoriatic arthritis.A review of disease activity measures for psoriatic arthritis: what is the best approach?Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR)Patient-Reported Outcomes in Psoriatic Arthritis.Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).Up-regulation of CD64-expressing monocytes with impaired FcγR function reflects disease activity in polyarticular psoriatic arthritis.Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris.Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasoundSingapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings.Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy.Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients.Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations.Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study.Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.Consensus on the management of patients with psoriatic arthritis in a dermatology setting.Psoriatic nail involvement and its relationship with distal interphalangeal joint disease.Outcome measures of disease activity in inflammatory arthritis.Disparity between ultrasound and clinical findings in psoriatic arthritis.
P2860
Q27693878-2CA8B3A0-2590-4206-810C-1A20B0DB722AQ28069592-CACE2351-2614-4F90-BD92-0918A064AD78Q33659004-834A3156-D388-4887-9B7D-4AF7690151DCQ34228353-F9D1A20E-F933-4900-9E1E-8570836D468CQ34769284-90C61865-DCB8-4EE4-8C23-04C7E2B2D383Q35257745-CCB2466B-189D-4988-94BE-85300F65C8E1Q35372388-3F8F08C9-2DB6-495D-A798-5C0BFC1421B3Q36182389-6DB1D1E5-1D59-4846-A117-EBE3A1261E91Q36833558-B5ED5DB9-B271-4426-97E7-4E91D7F957A0Q36942993-14D278F3-F3EC-4701-BF1F-21D506CEF4F4Q37416210-C3BFF23E-C152-4FE7-9E35-B2053BA2AC83Q37465518-641D3119-336B-4E5A-AD50-DD446DD604ADQ37465550-7F8FC188-2E0C-4FF6-AD9E-50F59826626CQ37585837-1BD6FEE4-B961-458F-B4F7-7F33D7D1F36FQ38114850-031F14D3-16C2-4474-891F-B565281F951CQ38189853-D28EB56F-89EF-4FD2-9CB6-15DB20DD2968Q38195568-D4006F6D-9730-446B-84B1-D684ADF74833Q38211315-E3336592-BAA3-440B-B17F-153ED764BD11Q38223570-2BCAF598-6CFD-4FD1-A64B-BDDFE98648BFQ38227264-AA940C1E-37D0-474A-98FD-D59EDC768454Q38236514-D84C456C-C85D-4CD9-8757-A65014EA6B89Q38238931-6624B1C7-8D08-467A-A202-336D926923FFQ38621658-16D5F98F-5B20-4873-93CC-5C4ADEEC9DE4Q38822369-4972C11C-D885-4315-B3B0-092A43E16296Q38868356-5C851ECE-F6DF-46A4-80E0-63C5E94C2896Q38994737-28C43604-5D67-43D8-9520-77A913159086Q39328197-BAFF51EF-DA70-4DE5-8152-46EB749CB70EQ41612744-55090A71-D8B8-4E40-8141-CCF17F277FB4Q42170098-1713AB6E-A706-480C-B986-C317AC1017B7Q46129663-B9849EFB-7348-408A-A1F1-74BC1A547790Q46155530-F5D9DBEB-FAF0-4074-9572-83FD8FB1D1A6Q46876696-29BDA3CB-D3D9-4C08-B24A-3244FF374503Q46958700-BCEE4CA4-6258-42A0-9CF2-4FC684FB5119Q47942672-BA2DD44F-8E86-42B0-8070-CE2D3152FE3FQ48004654-C788B097-C6A8-4099-925E-24B516B28496Q48123615-4C48980F-D568-4045-8D37-F490D4AA464FQ50002313-71A185F4-260D-42E6-9D8E-AF3F1CE09F66Q51725167-F5780D28-96BA-4B01-B99B-570D94B799F2Q52549412-8E266905-3D27-4F65-8430-E401DF0F178DQ53120487-4B80AB14-9BE6-48DF-9A00-516260F259FB
P2860
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Measures of psoriatic arthriti ...... thesitis Index (MEI), Leeds En
@nl
type
label
Measures of psoriatic arthriti ...... thesitis Index (MEI), Leeds En
@nl
prefLabel
Measures of psoriatic arthriti ...... thesitis Index (MEI), Leeds En
@nl
P2860
P3181
P356
P2093
Philip J. Mease
P2860
P304
P3181
P356
10.1002/ACR.20577
P407
P478
63 Suppl 11
P577
2011-11-01T00:00:00Z